Sign up USA
Proactive Investors - Run By Investors For Investors

Optibiotix Health - Microbiome Specialist Entering Commercial Phase

OptiBiotix Health Plc (LON:OPTI) focuses on managing and treating widespread, chronic medical conditions, such as obesity and high cholesterol, through the modulation of the human microbiome.
Optibiotix Health - Microbiome Specialist Entering Commercial Phase

Finally, it is worth highlighting the significant operating leverage of the business, as OptiBiotix is run on a very asset-light infrastructure. Products manufacturing is outsourced, and low fixed admin and selling expenses ensure a significant margin expansion, as revenue will keep growing over the next few years.

Full report is available via Capital Network website
View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Researches

no_picture_pai.jpg
November 30 2017

WideCells Group PLC ( LON:WDC) was originally set-up in 2012 in Portugal, as a provider of stem cell storage services for the Portuguese and Spanish markets. In 2016 the company was listed on the London Stock Exchange, raising £1.7mln - net of fees, largely used to establish a new research and storage facility in Manchester, UK and to support the ongoing international expansion.

no_picture_pai.jpg
November 02 2017
  • Preventing and treating diseases through the modulation of the microbiome is one of the most exciting frontiers of healthcare, and a fast growing market
  • OptiBiotix Health PLC (LON:OPTI), an innovative life sciences company focused on human microbiome, is rapidly transitioning from product development to the commercial stage with early revenues and commercial deals with major corporates including Tata and DSM
  • Underpinned by a strong scientific rationale and clinical studies, OptiBiotix Health PLC (LON:OPTI) products help managing significant health problems as weight loss, high cholesterol and hypertension
  • OptiBiotix Health PLC (LON:OPTI) commercial push is currently directed towards the rapidly growing consumer health market
  • A rich deal pipeline is likely to translate in material revenue growth (£1mln+) within 12 months
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use